Two people take the same pre-workout, same dose, same thirty minutes before training. One locks in. The other feels nothing — or worse, feels sluggish halfway through. You have watched this happen, at the gym, over coffee, in every conversation where someone insists caffeine does nothing while the person beside them runs on it.
Tolerance. Body weight. "I'm just not a caffeine person." The explanations sound reasonable until you learn that weight-adjusted doses produce the same split.
Why Caffeine Affects Some People More Than Others
A gene called CYP1A2 builds the enzyme responsible for breaking down over 95% of the caffeine in your body. One variant runs the process fast. Another runs it at medium speed. A third runs it slow. Which version you carry was fixed at birth — and it determines whether caffeine is fuel or friction.
Caffeine response is determined by your CYP1A2 genotype — a single gene that controls how fast your body breaks down caffeine. Fast metabolizers (about half the population) see clear performance benefits. Nearly 43% show no measurable response. And roughly 8% are slow metabolizers for whom the same dose that helps others actively impairs their performance, making them measurably slower.
— Guest et al. 2018 · Medicine & Science in Sports & Exercise · n=101
A 2018 study was the first to genotype competitive athletes for all three CYP1A2 variants and track what happened when each group got the same weight-adjusted caffeine dose before a cycling time trial. The results split into three clean lines.
Fast metabolizers finished 6.8% quicker than they did on placebo. The middle group — representing 43% of the athletes — showed zero measurable change. And the slow metabolizers?
They finished 13.7% slower on the same dose that made the first group faster.
Not "no benefit." Active impairment. The caffeine that sharpened one athlete's ride dragged another's backward by more than two minutes over the same distance. Among the fast metabolizers, 82% improved. Among the slow metabolizers, 12% did.
Fast metabolizers: 6.8% faster. 82% improved.
Middle metabolizers: Zero measurable change at any dose.
Slow metabolizers: 13.7% slower. 12% improved.
Half the athletes tested were fast metabolizers. Forty-three percent landed in the middle. Eight percent were slow — and that group had spent years hearing that caffeine "just doesn't work for them," when it had actually been working against them.
The mechanism is the enzyme itself. If your CYP1A2 runs fast, caffeine converts quickly into paraxanthine — the byproduct that sharpens focus and delays fatigue — before the caffeine itself has time to linger. If your version runs slow, caffeine stacks. It stays in your system too long, constricts blood vessels when they need to open, and the dose that primed someone else is now quietly undercutting yours.
The intuitive fix — take more — makes it worse. Slow metabolizers given a higher dose didn't break through. The impairment deepened. More caffeine, slower performance. The direction was set by the gene. The dose only scaled the magnitude.
The data comes from male endurance athletes on a cycling time trial — whether the same three-way split holds for strength training, for women, or for someone whose main caffeine decision is an afternoon coffee hasn't been proven the same way. The impairment in the slow group was stark enough to hold with a small number of slow metabolizers in the study. Still, the population it has been directly measured in is narrow.
Every caffeine decision you have ever made — the dose, the cutoff time, whether to cycle off or push through tolerance — assumed the molecule worked the same way in your body as in everyone else's. If it does, those decisions stand. If it doesn't, the math on how much of an edge caffeine actually gives you changes before you touch the dose.